Immunocore Plc, a UK company developing T cell receptor bispecific immunotherapies, has announced two new appointments. Ralph Torbay joins from AstraZeneca Plc as new head of commercial affairs, and Roy S Herbst becomes a member of its board of directors. Mr Torbay has a background in strategy, marketing and sales and over the past four years, has launched three oncology drugs.
Dr Herbst previously served as a member of Immunocore’s scientific advisory board. He is a specialist in lung cancer treatment and research, and is chief of medical oncology at the Yale Cancer Center and Smilow Cancer Hospital in New Haven, US.
Immunocore announced the appointment on 16 February 2021
Copyright 2021 Evernow Publishing Ltd